Is the Wegovy and Mounjaro Era Over? What Exactly Is the New Oral Weight-Loss Drug ‘Poundaio’?

Recently, injectable obesity treatments such as Wegovy and Mounjaro have gained tremendous popularity. However, access has been limited because of the burden of self-administering injections every week, high costs, and the challenges of cold-chain distribution.

A new treatment designed to overcome these limitations received approval from the U.S. FDA in April 2026. A New Oral Obesity Medication, “Poundaio” (Generic Name: Orforglipron)This new treatment is attracting considerable attention. We will take a comprehensive look at how it differs from existing therapies, what effects it may offer, and the scientific principles behind its action.

1. The Evolution of Obesity Treatments: From GLP-1 Injections to Oral Medications

• Why do we gain weight? : When you eat, in the intestines... GLP-1 hormoneThat hormone is released and sends signals of fullness to the brain, but in people with obesity, the secretion itself decreases and the body's satiety "brake" becomes less responsive.
• The emergence of injectable treatments : Novo Nordisk's Wegovy (semaglutide) is an injectable medication designed by modifying the structure of GLP-1, which is normally broken down quickly in the body, allowing it to remain active for a longer period. Eli Lilly's... MounjaroEli Lilly's medication produced greater weight-loss effects by stimulating both the GLP-1 and GIP receptors at the same time.
• The limitations and challenges of oral medications : Peptide (protein)-based oral medications had limitations because they were easily broken down by stomach acid and digestive enzymes, requiring strict dosing routines for proper absorption, such as taking them on an empty stomach with 120 mL of water.

Non-peptide small molecule

• Chemically engineered new key : Orforglipron, the active ingredient in Poundaio, Orforglipronis not a protein (peptide) but a chemically synthesized Non-peptide small moleculeis.
• Acid-resistant structure : Unlike conventional keys that simply copy the hormone itself, it is a newly designed key created from scratch by analyzing the structure of the lock, so it does not dissolve in stomach acid. Therefore, it can be taken without special absorption enhancers (SNAC) or strict fasting routines. Take it conveniently anytimeCan be taken conveniently at any time.

Effectiveness, Side Effects, and Price Comparison

• Weight-loss effect : According to the ATTAIN clinical trial results, taking the highest dose (36 mg) for 72 weeks resulted in Average body weight decreased by 12.4%Although this figure may be lower than that reported for Wegovy (about 15%) or Mounjaro/Zepbound (about 20%), a direct comparison with oral Wegovy (16.6%) is difficult because of differences in patient populations and clinical trial conditions.
• People with diabetes : In the ACHIEVE 3 (SURPASS/ACHIEVE series) trial, when compared over 52 weeks in patients with type 2 diabetes, Poundaio 36 mg showed superior results to oral Wegovy 14 mg in both blood sugar control and weight loss.
• Economic efficiency and ease of distribution : In the United States, the cost starts at $25 per month (about KRW 34,000) with insurance coverage and $149 per month (about KRW 200,000) for self-paying patients. Does not require refrigeration or cold-chain distribution Significantly reduced distribution costs and barriers.

Future Outlook for Domestic Launch

• : At the time of FDA approval, Eli Lilly had submitted regulatory applications in more than 40 countries worldwide, and Korean hospitals also participated in ATTAIN-2, a global clinical trial.
• Considering that the review period for new drugs by South Korea's Ministry of Food and Drug Safety (MFDS) is typically around 10 months on average, Between late 2026 and mid-2027Is expected to be launched in South Korea between late 2026 and mid-2027. As a small-molecule drug, it is expected to be priced lower than injectable treatments.